Benefits of FLEXBUMIN 25% [Albumin (Human)], 25% Solution

FLEXBUMIN uses Baxter’s proprietary GALAXY flexible container system, which has numerous advantages.

The GALAXY container is a 4-layer system which is a proven technology used extensively with pharmaceutical products.

The FLEXBUMIN GALAXY container is convenient:

Ready-to-use
Reduced risk of breakage compared to glass bottles
Can be used with vented and nonvented administration sets¹
60% less storage space than glass¹
40% less weight than glass¹
Compatible with hospital inventory storage systems

The FLEXBUMIN GALAXY container is safe:

It has a multilayer system that maintains albumin quality¹
All container components are latex free¹
No risk of aluminum leaching¹
Flexible container does not contain polyvinyl chloride (PVC)¹
Meets U.S. Pharmacopia requirements²

FLEXBUMIN 25% [Albumin (Human)]

FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. FLEXBUMIN 25% is indicated for hypovolemia, hypoalbuminemia due to general causes, burns, adult respiratory distress syndrome (ARDS), and nephrosis, and for use during or prior to cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).

Important Risk Information for FLEXBUMIN 25%

FLEXBUMIN 25% is contraindicated in patients with cardiac failure, in patients with severe anemia and in patients with a history of allergic reactions to human albumin.

Do not use if turbid. Do not begin administration more than 4 hours after the container has been entered.

Do not use Sterile Water for Injection as a diluent. There exists a risk of potentially fatal hemolysis and acute renal failure from the inappropriate use of Sterile Water for Injection as a diluent for FLEXBUMIN 25%. Acceptable diluents include 0.9% Sodium Chloride or 5% Dextrose in Water.

FLEXBUMIN 25% is made from pooled human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses and theoretically, the Creutzfeldt–Jakob disease (CJD) agent.

FLEXBUMIN 25% must be administered intravenously at a rate not to exceed 1 mL/min to patients with normal blood volume, due to the risk of developing circulatory overload and pulmonary edema.

When 25% albumin is infused, a rise in blood pressure necessitates careful observation to detect and treat severed blood vessels that may not have bled at a lower blood pressure.

Adverse reactions to FLEXBUMIN 25% are extremely rare, although nausea, fever, chills or urticaria may occasionally occur.

CAUTION: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before the administration of the fluid from the secondary container is complete.

Please see Preparation for Administration for FLEXBUMIN 25% in the Prescribing Information.

Please review the FLEXBUMIN 25% [Albumin (Human)] Prescribing Information for full prescribing details.

BUMINATE 5% [Albumin (Human)], USP, 5% Solution

BUMINATE 5% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 5% is indicated in hypovolemia, hypoalbuminemia, burns, and cardiopulmonary bypass surgery.

Please see Important Risk Information for BUMINATE 5% and Full Prescribing Information.

BUMINATE 25% [Albumin (Human)], USP, 25% Solution

BUMINATE 25% is a sterile, nonpyrogenic preparation of albumin in a single dosage form for intravenous administration. BUMINATE 25% is indicated in hypovolemia, hypoalbuminemia, burns, adult respiratory distress syndrome (ARDS), nephrosis, cardiopulmonary bypass surgery, and hemolytic disease of the newborn (HDN).

Please see Important Risk Information for BUMINATE 25% and Full Prescribing Information.

Data on file: Baxter Healthcare Corporation.
FLEXBUMIN Prescribing Information. Westlake Village, Calif: Baxter Healthcare Corporation; September 2009.